November 19, 2024

Merck’s Subcutaneous Keytruda Shows Non-Inferiority in Phase 3 Trial, Paving Way for Regulatory Discussions

5 months ago talkbio0Tagged Immunotherapy for cancer, Keytruda, Merck, non-inferiority, Phase 3 trial, regulatory, subcutaneous, submissions

Merck, Keytruda, subcutaneous, cancer immunotherapy, phase 3 trial, non-inferiority, regulatory submissions

FDA Issues Complete Response Letter to Astellas for IZERVAY Supplemental New Drug Application

5 months ago talkbio0Tagged Age related macular degeneration, Astellas, Complete, Geographic Atrophy, IZERVAY, New Drug Application, Response process, United States Food and Drug Administration

FDA, Astellas, IZERVAY, geographic atrophy, age-related macular degeneration, Complete Response Letter, supplemental New Drug Application

Unlocking Health Equity: Leveraging Comprehensive SDOH Market Insights for Enhanced Treatment, Access, and Adherence

5 months ago talkbio0Tagged Adherence, Adherence (attribute), Data Analytics, Health care facility, Health Equity, Market, outcomes, public health medicine (field), Social Determinants of Health

Social Determinants of Health (SDOH), Health Equity, Market Insights, Treatment Access, Adherence, Healthcare Outcomes, Data Analytics, Public Health

Pharmaceutical Industry’s Digital Transformation Halted by Persistent Skills Shortage

5 months ago talkbio0Tagged Digital skills, digital transformation, Drug Industry, Pharma, skill, Talent Acquisition

Digital transformation in pharma, Skills shortage, Pharmaceutical industry challenges, Talent acquisition, Digital skills gap

Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced

5 months ago talkbio0Tagged asset, cull, Drug Industry, Incyte, News [Publication Type]

Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry

Cybin’s Psychedelic Drug CYB003 Demonstrates Sustained Efficacy in Reducing Depression Symptoms Over 12 Months

5 months ago talkbio0Tagged Analog, CYB003, Effectiveness, Hallucinogens, MDD, Mental Depression, Sustained, Symptom reduction, Unipolar Depression

CYB003, psychedelic drug, depression treatment, sustained efficacy, 12-month symptom reduction, major depressive disorder (MDD), psilocin analog.

Neurogene Halts Development of Batten Gene Therapy NGN-101 Following FDA Denial

5 months ago talkbio0Tagged Denial (Psychology), disease research, gene therapy, Infrequent, Juvenile Neuronal Ceroid Lipofuscinosis, Neurogene, NGN-101, United States Food and Drug Administration

Neurogene, Batten disease, gene therapy, NGN-101, FDA denial, rare disease research

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

5 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease

J&J’s Icotrokinra (JNJ-2113) Achieves Significant Success in Phase 3 Trials for Moderate to Severe Plaque Psoriasis

5 months ago talkbio0Tagged Clinical Trials, Dental Plaque, IL-23 receptor antagonist, JNJ-2113, Phase, Protagonist Therapeutics, Psoriasis

JNJ-2113, icotrokinra, IL-23 receptor antagonist, plaque psoriasis, Phase 3 clinical trials, Johnson & Johnson, Protagonist Therapeutics

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

5 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction